LONDON, November 22, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
On Thursday, November 21, 2013, all three benchmark indexes of the US equity market edged higher with the S&P 500, the Dow Jones Industrial Average, and the NASDAQ Composite rising 0.81%, 0.69%, and 1.22%, respectively. Shares in the biotechnology industry ended on a higher note, tracking gains in the broader market. The major movers in the sector included Arena Pharmaceuticals Inc. (NASDAQ: ARNA), Geron Corporation (NASDAQ: GERN), Incyte Corporation (NASDAQ: INCY), and Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at:
On Thursday, shares in Arena Pharmaceuticals Inc. surged, as the broader market posted gains. The company's shares closed the day 4.19% higher at $5.72, after trading between $5.46 and $5.72. A total of 4.53 million shares were traded, which is below the daily average volume of 5.37 million. The company's shares have gained 2.60% in the previous three trading sessions and 30.30% in the last one month, outperforming the S&P 500, which has advanced 0.24% and 2.93% during the respective periods. Further, Arena Pharmaceuticals Inc.'s stock is trading above its 50-day moving average of $4.99. Sign up for free report on ARNA at:
Geron Corp.'s stock surged 3.07% on Thursday, to end the day at $5.20, up from the previous day's closing price of $5.05. The company's shares oscillated between $5.05 and $5.24 during the trading session. A total of 2.30 million shares were traded, which is below the daily average volume of 4.03 million. The company's shares have rallied 25.30% in the last one month and 258.62% in the previous three months, outperforming the S&P 500, which has gained 2.93% and 9.32% during the respective periods. Additionally, Geron Corp.'s stock is trading above its 50-day and 200-day moving averages of $3.75 and $1.92, respectively. GERN free technical report can be accessed by signing up at:
On Thursday, Incyte Corp.'s stock finished at $47.94, which is 2.37% higher than the previous day's closing price of $46.83. The company's shares vacillated between $46.92 and $48.41 during the trading session. A total of 1.07 million shares were traded, which is below the daily average volume of 2.06 million. The company's shares have gained 28.97% in the last one month and 33.02% in the previous three months, outperforming the S&P 500, which has gained 2.93% and 9.32% during the respective periods. Moreover, Incyte Corp.'s stock is trading near its 52-week high of $48.45 and above its 50-day and 200-day moving averages of $39.04 and $27.66, respectively. A free report on INCY can be accessed by registering at:
Shares in Spectrum Pharmaceuticals Inc. fluctuated between $9.31 and $9.50 before ending Thursday's session 0.11% higher at $9.36. A total of 0.47 million shares were traded, which is below the daily average volume of 0.83 million. The company's shares have gained 13.04% in the last one month and 22.83% in the previous three months, outperforming the S&P 500, which has gained 2.93% and 9.32% during the respective periods. Furthermore, Spectrum Pharmaceuticals Inc.'s stock is trading above its 50-day and 200-day moving averages of $8.68 and $8.47, respectively. Register with AAA Research Reports and download research on SPPI for free at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE AAA Research Reports